Dizal presents updated PhII PTLC data, plans to file for accelerated approval in the US next year

Dizal said its pe­riph­er­al T-cell lym­phoma drug can­di­date showed pos­i­tive ef­fi­ca­cy and safe­ty in a Phase II reg­is­tra­tional tri­al, paving the way for a US fil­ing in what has been a chal­leng­ing in­di­ca­tion to se­cure full ap­proval.

The sin­gle-arm JACK­POT8 Part B in­ves­ti­gat­ed goli­doc­i­tinib — a JAK1 se­lec­tive in­hibitor — in 104 peo­ple with re­lapsed or re­frac­to­ry pe­riph­er­al T-cell lym­phoma (PT­CL), and the full da­ta were re­leased Sun­day at the ASH meet­ing in San Diego.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.